NasdaqGM:FLGTHealthcare
Fulgent Genetics (FLGT) Loss Widening In Q4 2025 Tests Bullish Growth Narratives
Fulgent Genetics (FLGT) just posted its FY 2025 numbers, with fourth quarter revenue of US$83.3 million and a basic EPS loss of US$0.76, alongside net income excluding extra items at a loss of US$23.4 million. The company has seen quarterly revenue move from US$76.2 million in Q4 2024 to US$83.3 million in Q4 2025, while basic EPS shifted from a loss of US$0.19 to a loss of US$0.76 over the same stretch. This sets up a results season where the key question is how much of that top line is...